-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $15

Benzinga·05/01/2025 19:52:43
Listen to the news
Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $16 to $15.